Orbito-scleral-sinus invasion of basal cell carcinoma in an immunocompromised patient on vismodegib

Orbit. 2021 Apr;40(2):155-158. doi: 10.1080/01676830.2020.1753783. Epub 2020 Apr 14.

Abstract

A 45-year-old man presented with a progressively enlarging left lower lateral eyelid lesion. The initial biopsy was inconclusive; however, a repeat biopsy 5 years later revealed infiltrative morpheaform basal cell carcinoma with sclerosis. Two years later, the patient presented with ophthalmoplegia of the left eye. Computed tomography illustrated a heterogeneous enhancing soft tissue mass in the inferolateral orbit with erosion into the globe. Despite treatment with vismodegib for 1 year, the lesion progressed to involve the entire left lower eyelid and corneal-scleral junction with adjacent maxillary sinus invasion. The patient tested positive for human immunodeficiency virus and underwent a left orbital exenteration followed by adjuvant radiotherapy. The patient remained stable with no evidence of recurrent disease or distant metastasis 2 years after exenteration. This rare case highlights a neglected basal cell carcinoma in those immunocompromised with histopathological correlation of the aggressive disease on to the globe.

Keywords: Basal cell carcinoma; basal cell carcinoma of the eyelid; human immunodeficiency virus; orbital malignancy; vismodegib.

Publication types

  • Case Reports

MeSH terms

  • Anilides / therapeutic use
  • Carcinoma, Basal Cell* / drug therapy
  • Humans
  • Immunocompromised Host
  • Male
  • Middle Aged
  • Pyridines
  • Skin Neoplasms*

Substances

  • Anilides
  • HhAntag691
  • Pyridines